These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37903524)

  • 1. Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada.
    Skowronski DM; Kaweski SE; Irvine MA; Chuang ESY; Kim S; Sabaiduc S; Reyes RC; Henry B; Sekirov I; Smolina K
    CMAJ; 2023 Oct; 195(42):E1427-E1439. PubMed ID: 37903524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada.
    Skowronski DM; Kaweski SE; Irvine MA; Kim S; Chuang ESY; Sabaiduc S; Fraser M; Reyes RC; Henry B; Levett PN; Petric M; Krajden M; Sekirov I
    CMAJ; 2022 Dec; 194(47):E1599-E1609. PubMed ID: 36507788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
    COVID-19 Cumulative Infection Collaborators
    Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of SARS-CoV-2 infection hospitalisation and infection fatality ratios over 23 months in England.
    Eales O; Haw D; Wang H; Atchison C; Ashby D; Cooke GS; Barclay W; Ward H; Darzi A; Donnelly CA; Chadeau-Hyam M; Elliott P; Riley S
    PLoS Biol; 2023 May; 21(5):e3002118. PubMed ID: 37228015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
    COVID-19 Forecasting Team
    Lancet; 2022 Apr; 399(10334):1469-1488. PubMed ID: 35219376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
    Laxminarayan R; B CM; G VT; Arjun Kumar KV; Wahl B; Lewnard JA
    Lancet Infect Dis; 2021 Dec; 21(12):1665-1676. PubMed ID: 34399090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.
    Tunheim G; Rø GØI; Tran T; Kran AB; Andersen JT; Vaage EB; Kolderup A; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Mar; 16(2):204-212. PubMed ID: 34751488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality.
    Marziano V; Guzzetta G; Menegale F; Sacco C; Petrone D; Mateo Urdiales A; Del Manso M; Bella A; Fabiani M; Vescio MF; Riccardo F; Poletti P; Manica M; Zardini A; d'Andrea V; Trentini F; Stefanelli P; Rezza G; Palamara AT; Brusaferro S; Ajelli M; Pezzotti P; Merler S
    Influenza Other Respir Viruses; 2023 Aug; 17(8):e13181. PubMed ID: 37599801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada.
    Tanunliong G; Liu AC; Kaweski S; Irvine M; Reyes RC; Purych D; Krajden M; Morshed M; Sekirov I; Gantt S; Skowronski DM; Jassem AN
    Front Immunol; 2022; 13():836449. PubMed ID: 35401521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age- & sex-specific infection fatality ratios for COVID-19 estimated from two serially conducted community-based serosurveys, Chennai, India, 2020.
    Vivian Thangaraj JW; Kumar MS; Velusamy S; Girish Kumar CP; Selvaraju S; Sabarinathan R; Jagadeesan M; Hemalatha MS; Bhatnagar T; Murhekar MV
    Indian J Med Res; 2021 May; 153(5&6):546-549. PubMed ID: 34528527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada.
    Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Fafard J; Gilca R; Talbot D; Ouakki M; Febriani Y; Deceuninck G; De Wals P; De Serres G
    Lancet Healthy Longev; 2023 Aug; 4(8):e409-e420. PubMed ID: 37459879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution and interpretation of seroprevalence of SARS-CoV-2 antibodies among South African blood donors from the Beta to Omicron variant-driven waves.
    Vermeulen M; Mhlanga L; Sykes W; Cable R; Coleman C; Pietersen N; Swanevelder R; Glatt TN; Bingham J; van den Berg K; Grebe E; Welte A
    Vox Sang; 2024 Mar; 119(3):242-251. PubMed ID: 38156504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and Deaths Among Adults Aged ≥18 Years - 18 U.S. Jurisdictions, September 2021-December 2022.
    Ma KC; Dorabawila V; León TM; Henry H; Johnson AG; Rosenberg E; Mansfield JA; Midgley CM; Plumb ID; Aiken J; Khanani QA; Auche S; Bayoumi NS; Bennett SA; Bernu C; Chang C; Como-Sabetti KJ; Cueto K; Cunningham S; Eddy M; Falender RA; Fleischauer A; Frank DM; Harrington P; Hoskins M; Howsare A; Ingaiza LM; Islam AS; Jensen SA; Jones JM; Kambach G; Kanishka F; Levin Y; Masarik JF; Meyer SD; Milroy L; Morris KJ; Olmstead J; Olsen NS; Omoike E; Patel K; Pettinger A; Pike MA; Reed IG; Slocum E; Sutton M; Tilakaratne BP; Vest H; Vostok J; Wang JS; Watson-Lewis L; Wienkes HN; Hagen MB; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(25):683-689. PubMed ID: 37347715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.
    Chen X; Yan X; Sun K; Zheng N; Sun R; Zhou J; Deng X; Zhuang T; Cai J; Zhang J; Ajelli M; Yu H
    medRxiv; 2022 Jul; ():. PubMed ID: 35898339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population-based cohort study in British Columbia, Canada.
    Russell SL; Klaver BRA; Harrigan SP; Kamelian K; Tyson J; Hoang L; Taylor M; Sander B; Mishra S; Prystajecky N; Janjua NZ; Zlosnik JEA; Sbihi H
    J Med Virol; 2023 Jan; 95(1):e28423. PubMed ID: 36546412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.
    Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ
    Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.